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Organisation of RNAs into functional subgroups that are translated in response to extrinsic and intrinsic factors underlines a
relatively unexplored gene expression modulation that drives cell fate in the same manner as regulation of the transcriptome
by transcription factors. Recent studies on the molecular mechanisms of inﬂammatory responses and haematological disorders
indicate clearly that the regulation of mRNA translation at the level of translation initiation, mRNA stability, and protein
isoform synthesis is implicated in the tight regulation of gene expression. This paper outlines how these posttranscriptional
control mechanisms, including control at the level of translation initiation factors and the role of RNA binding proteins, aﬀect
hematopoiesis. The clinical relevance of these mechanisms in haematological disorders indicates clearly the potential therapeutic
implicationsandtheneedofmoleculartoolsthatallowmeasurementattheleveloftranslationalcontrol.Althoughtheimportance
of miRNAs in translation control is well recognised and studied extensively, this paper will exclude detailed account of this level of
control.
1.Introduction
Hematopoietic stem cells (HSCs) have a life-long capacity to
replenish the stem cell compartment and give rise to mul-
tipotent progenitors. These progenitors expand to maintain
the hematopoietic compartment and diﬀerentiate into vari-
ous blood lineage progenitors. Lineage positive progenitors
are committed for diﬀerentiation into mature blood cells.
Transcription factorshave a pivotal role in hematopoiesis
to maintain a gene expression program that endows self-re-
newal properties to HSCs and enables commitment and dif-
ferentiation into diﬀerent blood cell lineages [1]. The upreg-
ulation of both PU.1 and Gata-1 reprograms HSC to be-
come common myeloid progenitors (CMPs) [2]. The CMPs
undergo further lineage divergence into megakaryocyte/ery-
throid progenitors (MEPs) and granulocyte/monocyte pro-
genitors (GMPs) upon Gata-1 and PU.1 mutual exclusive
expression, respectively. Commitment to the erythroid lin-
eage is characterized by the expression of erythroid-speciﬁc
transcription factors Gata-1, Eklf, and Nfe2 determining the
erythroid program.
Upon commitment, the balance between proliferation
and diﬀerentiation of lineage-speciﬁc progenitors is under
tight control, to maintain the progenitor pool and ensure
maturation in response to physiological demand. The pro-
duction of increased numbers of mature blood cells during
stress situations such as inﬂammation or hypoxia requires
higher progenitor proliferation rates. Concurrently, feedback
mechanisms must be closely coordinated to repress progeni-
tor proliferation when the stress is over [3]. The human bone
marrow must replace 1011 erythrocytes daily under normal
physiological erythropoiesis. Gene expression is regulated at
the transcription level, producing a cell-speciﬁc mRNA pool.
Subsequent control of mRNA translation enables the cells
to further adapt to environmental and developmental cues.
Translation regulation (i) permits fast cellular responses to
growthfactors,inducingspeciﬁcproteinstobeexpressed,(ii)
selectiveexpressionofdiﬀerentproteinisoformsfromagiven
transcript, and (iii) induction of expression of pro-apoptotic
proteins when the transcription program is inhibited. Trans-
lation Initiation is an important level of translation control.
Cap-dependent translation initiation depends on two major2 Comparative and Functional Genomics
limiting steps: (i) the formation of the initiation complex by
release of the cap-binding initiation factor eIF4E from its
binding factor 4E-BP and (ii) binding of the ternary complex
(TC) consisting of GTP-loaded translation initiation factor
2 (eIF2:GTP) plus a methionine-loaded initiator tRNA
(tRNAi
met) to the 40S ribosome subunit. Cap-independent
translationinitiationdependsonaninternalribosomalentry
site (IRES) in the transcript that has to bind IRES transacti-
vating factors (ITAFs). The biochemistry of translation initi-
ation has been extensively reviewed [4, 5]. We will focus on
the importance of translation initiation for haematopoiesis.
2. Growth Factor-Dependent Proliferation of
Hematopoietic Progenitors
The main regulator of erythropoiesis is the glycoprotein hor-
mone Erythropoietin (Epo), produced in the kidney in re-
sponse to oxygen tension in the blood. The function of Epo
initiates from the speciﬁc interaction to its cell surface re-
ceptor (EpoR). In stress erythropoiesis, stem cell factor (cKit
ligand) and glucocorticoids (GR) work in concert with Epo
to induce expansion of progenitors in the mouse spleen
[6, 7]. The requirement for SCF in acute erythroid expansion
was demonstrated by the observation that inhibiting c-Kit
antibodies abolished splenic hematopoiesis upon induction
of haemolytic anaemia in mice, while the antibodies had no
eﬀect on steady-state erythropoiesis [6].
Epo and SCF transduce signals via multiple cooperating
pathways in erythroid progenitors [7–10], among which the
activation of the PI3K pathway. Although both Epo and SCF
activate PI3K in erythroid progenitors, the eﬃciency with
which downstream signalling pathways are activated shows
large diﬀerences [11, 12], suggesting diﬀerential susceptibil-
ity to feedback pathways. Activation of PI3K results in pho-
sphorylation and activation of PKB and subsequently of
mTOR (Figure 1). In turn, mTOR phosphorylates and acti-
vates S6K (Rps6kb1; p70S6Kinase) and 4EBP (4E-Binding
Protein) [13]. In erythroblasts, only SCF can induce full
phosphorylation of 4EBP [14]. PP2A is the main phospha-
tase acting on S6K and 4EBP1 and thereby the main anta-
gonist of mTOR function in erythroblasts (Figure 1).
4EBP hyperphosphorylation results in the release of the
mRNA cap-binding factor eIF4E (eukaryotic Initiation Fac-
tor 4E) [15]. Subsequently, eIF4E can bind the scaﬀold pro-
tein eIF4G, which enables the formation of an eIF4F scan-
ningcomplexcontainingeIF4E,eIF4G,andtheRNAhelicase
eIF4A. eIF4F associates with several other translation factors
including the 40S small subunit of the ribosome and the
associated ternary complex consisting of eIF2:tRNAi
met [5].
This preinitiation complex scans the 5UTR for the ﬁrst
AUG codon in an appropriate sequence context [16]. There
the ribosome associates and methionine is deposited at the
P-site and eIF2 is released [5, 17]. The cap-binding eIF4E
protein is a rate limiting factor in the formation of the
preinitiation complex [18] and therefore its release upon
phosphorylation of 4EBP is a crucial control mechanism
in polysome recruitment of mRNAs. In addition, eIF4E is
phosphorylated by MAP-kinase signal-integrating kinases
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Figure 1: The PI3K/PKB/mTOR pathway controls mRNA transla-
tion. SCF-receptor activation results in recruitment of PI3K to the
receptor, which generates phosphorylates membrane lipids (PIP3)
that form an anchor for the PH-domain containing kinases PDK1
and PKB. PIP3 is dephosphorylated by the tumour suppressor
PTEN, which silences the PI3K-pathway. At the membrane PDK1
phosphorylates PKB, which phosphorylates the tuberous sclerosis
tumour suppressor genes Tsc1 and Tsc2. Upon phosphorylation
these genes release the GTPase Rheb to activate mTOR. Activation
of mTOR results in phosphorylation of p70S6kinase (S6K) and
eIF4E-binding protein (4E-BP). Upon phosphorylation, 4E-BP
releases the cap-binding translation initiation factor 4E (eIF4E),
which allows for association of eIF4E with the proteins that form
the eIF4F scanning complex and with the 40S ribosomal subunit
[4].
Mnk1 and Mnk2 [19, 20] in response to insulin and stress
[21]. The role of eIF4E phosphorylation is still controversial.
2.1. Translation Initiation Sensitivity to eIFs: Regulation of
eIF4F-Sensitive Transcripts. Although the preinitiation com-
plex consists of general translation factors, it scans mRNAs
with a short and simple 5 Untranslated Region (UTR) much
more eﬃciently than mRNAs with a long and structured
5UTR [22]. Structured mRNAs require a higher density
of preinitiation complexes to maintain an open structure,
which renders them more sensitive to the concentration
of eIF4F complexes in the cell. Well-known examples are
growth promoting proteins such as VEGF, MYC, and ODC
[22]. PI3K-dependent, selective polysome recruitment of
mRNA is important in v-Ras/v-Akt-transformed glioblas-
toma cells [23] and in metastasis of human epithelial cells
[24]. Transcripts that are speciﬁcally recruited to polysomes
upon overexpression of eIF4E have been identiﬁed in mouse
and human cells [25, 26].
Proliferation of erythroid progenitors under conditions
that mimic stress erythropoiesis is strictly dependent on
PI3K activity [11, 27]. Overexpression of eIF4E abrogated
the requirement for SCF-induced PI3K activation, whichComparative and Functional Genomics 3
suggested a role of selective polysome recruitment of tran-
scriptwithacomplexRNAstructure[12].Genomewidepro-
ﬁling of both total and polysome-associated mRNAs in an
erythroblast cell line, I/11, cultured in presence or absence
of growth factors identiﬁed a large number of constitu-
tively expressed transcripts that are selectively translated in
responsetoPI3Kactivation,oruponoverexpressionofeIF4E
[14]. This list of eIF4E-sensitive transcripts included alpha4,
a subunit of protein phosphatase 2a (PP2a). PP2A exists in
various complexes that shift target speciﬁcity depending on
the binding of regulatory components. mTOR modulates
the formation of the PP2A-α4 complex sequestrating the
phosphatase activity away from its own downstream targets
4EBP and S6K [28–31]. Constitutive expression of alpha4 in
erythroidprogenitorscompletelyblockederythroiddiﬀeren-
tiation and endowed erythroblast with long-term prolifera-
tion in the absence of SCF. It maintained the activation
state of the mTOR targets 4EBP and p70S6k in the presence
of Epo alone and enhanced polysome recruitment of other
eIF4E-senstive transcripts [14]. This further underlines the
importance of eIF4E-dependent translation and of the
proteins controlled by this mechanism. Among them are
indeed several proteins that are essential for erythropoiesis
such as Nme2 [14, 32, 33] and the SNARE protein Use1 that
is essential for retrograde transport of vesicles from the Golgi
to the ER [34].
Mutations that enhance translation initiation eﬃciency
have been implicated in the aggressiveness of various human
cancers including Acute Myeloid Leukemia (AML) [35, 36].
Constitutive activation of PI3K and mTOR occurs at high
frequencyinAML[37].MostlythecauseofconstitutivePI3K
activation is unknown, but mutations in the receptor kinases
cKIT and FLT3 are candidates. The D816V mutation in the
kinase domain of cKit activates the PI3K/PKB/mTOR path-
way and confers sensitivity to rapamycin [38]. Interestingly,
rapamycin induces cell cycle arrest and apoptosis in patient-
derived neoplastic mast cells harbouring the D816V cKIT,
but not in normal human cord-blood-derived mast cells.
This implies that inhibitors targeting translation initia-
tion regulators are therapeutic candidates in the treatment
of aggressive systemic mastocytosis (associated with cKIT
D816V) and in AML harbouring the D816V cKIT mutant
(presentin10to40%ofcore-bindingfactorleukaemia[39]).
Enhanced eIF4E-dependent translation of transcripts
with a structured 5UTR also contributes to chronic myel-
ogenous leukaemia (CML). Leukemic transformation of he-
matopoietic progenitors by the BCR/ABL fusion protein
depends on PI3K activation, which will enhance 4EBP pho-
sphorylation and eIF4E release. In addition, BCR/ABL in-
duces expression of SET, which subsequently acts as an
inhibitory regulatory subunit of PP2A similar to α4[ 14, 40].
Notably, the leukaemic potential of BCR/ABL-expressing
cells can be inhibited by pharmacological activation of the
phosphatase pp2a [41].
Pharmacological inactivation of mTOR with rapamycin
reduces neoplastic proliferation in PTEN deﬁcient mice,
and reverses tumour growth in cancer cells characterised by
activated PKB [42]. In AML, however, trials with rapamycin
have been put on halt because rapamycin induced a feedback
pathway resulting in further PKB activation [43]. Given the
role of the Pp2a regulatory subunit α4, reactivation of the
phosphatase, pp2a, oﬀers a potential alternative treatment to
therapy-resistant patients [44].
2.2. Translation Initiation Sensitivity to eIFs: eIF2α Phospho-
rylation and AUG Selection. The second limiting translation
factor next to eIF4E is eIF2, a GTPase that is associated with
methionine-loaded initiator tRNA only in its GTP-bound
state. This complex of eIF2:GTP/tRNAi
met is known as the
ternary complex (TC) [5]. The GTPase activity of eIF2 is
activated by recognition of an AUG codon and depends on
the sequence context. The better an initiation codon resem-
bles the consensus sequence (A/GnnAUGG), the higher the
chance that the eIF2 GTPase activity is triggered and methio-
nine is delivered to the P-site of the ribosome [45]. This
then leads to release of eIF2:GDP. In addition to availability,
also the activity of eIF2 is regulated. The initiation factor
eIF5 increases GTPase activity and increases the probability
that methionine is deposited at the P-site of the ribosome at
a start codon in a less optimal context [17]. The eIF2 is a
trimeric protein that is regulated by phosphorylation of the
eIF2α subunit. Phosphorylation inhibits the recovery of
eIF2:GTP from eIF2:GDP by protein eIF2B, and thereby the
reassociation with tRNAi
met. The kinases involved in eIF2
phosphorylation are activated by lack of haem (HRI), un-
folded proteins in the ER (PERK), double strand RNA (RNA
viruses; PKR), or lack of amino acids (GCN2) [46]. In
the hematopoietic system, HRI is extremely important in
erythropoiesisbecauseitcoordinateshaemoglobinsynthesis.
It links iron availability and haem synthesis to the translation
of globin chains [47]. Phosphorylation of eIF2 results in
translation of Atf4 (activating transcription factor 4) and
subsequent transcription of Gadd34. Gadd34 is an activating
regulatorysubunitofphosphatasePp1thatisabletodephos-
phorylate eIF2-P. Mice lacking this feedback regulation
develop severe anemia [48].
Similar to eIF4E, also eIF2 availability has consequences
for both the overall protein synthesis rate and the translation
oftranscriptsthatcarryregulatorysequencesintheir5UTR.
The phosphorylation level of eIF2 speciﬁcally controls
translationoftranscriptswithupstreamopenreadingframes
(uORFs). Following the translation of a short uORF, the
preinitiation complex lacking eIF2 continues scanning. Dur-
ing scanning the TC will reassociate to enable translation ini-
tiationatthenextAUGstartcodoninanappropriatecontext.
TheavailabilityofTCwilldeterminehowfasttranslationcan
reinitiate. Thus, eIF2 phosphorylation renders translation
dependent on the distance between an uORF and the AUG
start codon. Notably, the majority of transcripts that are
dependent on SCF-induced PI3K activity and on availabil-
ity of eIF4E in erythroblasts also contain several uORFs,
including the previously mentioned transcripts encoding
Nme2, Use1, and α4. Translation of these transcripts is
hypersensitive not only to growth factor signalling but also
to inhibition by oxidative stress, or iron availability.
Thetranscriptencodingthrombopoietin(TPO)contains
7 uORFs of which the last uORF overlaps with the TPO start
codon [49]. In hereditary thrombocytosis (HT) mutations4 Comparative and Functional Genomics
that deregulate translation of some of these uORFs cause
high levels of TPO expression and thrombosis.
Notably, the transcripts of several Ets-family members,
Scl/Tal,andC/EBPαandβcontainanupstreamORF(uORF)
that overlaps and is out of frame of the proper AUG start
codon of the full-length isoform of the transcription factor
[50, 51]. The uORF starts with a uAUG in a suboptimal Koz-
ak consensus and hence is only translated at enhanced activ-
ity and availability of eIF2:GTP and eIF4E. When the uORF
is translated, the initiation codon of the full-length pro-
tein is skipped and reinitiation at a downstream AUG codon
resultsinsynthesisofashorterproteinisoform.Inthecaseof
C/EBPα translation initiation at a downstream AUG results
in a truncated transcription factor protein that acts as a
dominant negative isoform [52].
TheimportanceoftherelativeabundanceofC/EBPαiso-
forms is evidenced by the occurrence of mutations in acute
myeloid leukaemia (AML) cases that inhibit translation of
the full-length C/EBPα protein [52]. The functional 30kDa-
truncated protein expressed in these patients was shown
to inhibit G-CSF receptor in 32Dcl3 cells induced to dif-
ferentiate into neutrophils [53]. In addition, C/EBPα is re-
quired for the generation of the GMP compartment and its
expression also denotes selectivity in diﬀerential commit-
ment to monocytic lineage [54]. In a subset of AML C/EBPα
is mutated [55]. Strikingly, two mutations are combined: an
N-terminal mutation on 1 allele and a C-terminal mutation
on the other allele. The N-terminal mutation abrogates the
long isoform of C/EBPα but allows for translation from the
downstream AUG start codon, which contributes to the phe-
notype of the AML [56].
Increasing evidence supports the importance of express-
ing diﬀerent isoforms that modulate lineage commitment in
hematopoieticcells.Theexpressionoftruncatedformsofthe
transcription factor, Stem Cell Leukaemia (Scl), is regulated
by diﬀerential initiation of translation [51] and results in
erythroid lineage diﬀerentiation. Expression of functional
isoforms due to diﬀerential translation has been described
for other hematopoietic transcription factors [50, 57]a n d
disruption of isoform ratios is implicated in disease [52, 53].
The list of transcripts regulated at the level of alternative
AUG usage in hematopoietic regulation is increasing. A
noveltechniquetoidentifytranslationstartcodonsindicated
that 65% of all transcripts expressed in mouse ES cells are
translated from at least 2 alternative start sites [58].
Translation initiation inhibition of growth regulatory
proteins (growth factors, cytokines, oncogenes, repressors
of tumour suppressor inhibitors, and others) is a known
phenomenon [59] and this may be extended to regulatory
proteins that attenuate cellular terminal diﬀerentiation.
2.3.TranslationInitiationSensitivitytoeIFs:Cap-Independent
Translation. Regulatory elements at the 5UTR of mature
transcripts render translation dependent on signalling or
other environmental conditions such as iron availability.
Some transcripts however have a highly structured 5UTR
meant to completely block cap-dependent translation ini-
tiation. Under the conditions that these proteins need
to be synthesized, cap-dependent translation initiation is
strongly decreased and translation initiation reverts to in-
ternal ribosome entry sites (IRESs). The structural complex-
ity of IRES elements argue in favour of their role as
translation inhibitors, although it is more correct to deﬁne
these structures as modulators of translation. For instance,
although the 5UTR of platelet-derived growth factor
(PDGF2) is long (1022bp), is structured and contains up-
stream ORFs, it is eﬃciently translated during megakaryocy-
tic diﬀerentiation via binding and activation of the IRES by
hnRNP C (Figure 2)[ 60]. Hence, speciﬁcity of IRES-media-
ted gene expression is determined by IRES trans-acting fac-
tors (ITAFs), representing a particular cellular state. In ad-
dition to diﬀerentiation, translation initiation starting from
an IRES is found in transcripts encoding proapoptotic
proteins or proteins required speciﬁcally during G2/M when
transcription is silenced by compaction of the DNA [61, 62].
IRES-dependent translation is less competitive for poly-
some recruitment than cap-dependent translation. There-
fore, IRES-dependent translation may be preferentially im-
paired when ribosome subunits are reduced, a situation that
is typical for Diamond Blackfan Anemia (DBA). Expression
proﬁlingofpolyribosome-boundmRNAsfromerythroblasts
identiﬁed a speciﬁc set of transcripts that are selectively lost
from polyribosomes upon reduced expression of Rps19 [63].
Among these mRNAs were transcripts encoding the Hsp70/
Hsc70 cochaperone Bag1 (Bcl-2-associated athanogene 1),
and the RNA binding protein Csde1 (cold shock domain
containing E1), both requiring an IRES for translation initia-
tion. Importantly, expression of BAG1 and CSDE1 was also
reduced in human erythroblasts cultured from peripheral
blood of DBA patients, whereas BAG1 and CSDE1 mRNA
level was constant or even elevated. Interestingly, Csde1
binds the IRES of several transcripts and controls IRES-me-
diated translation [64].
2.4. RNA-Binding Proteins: Transcript Stability and Transla-
tion Control. mRNA translation is regulated by activities of
the translation machinery components as described previ-
ously but also via regulation of proteins that bind to spec-
iﬁc mRNAs. RNA binding protein complexes attenuate ex-
pression by modulating stability, degradation, cellular local-
isation, and silencing of speciﬁc RNAs or subgroups of
mRNAs. The most studied RNA-binding proteins present
in ribonucleoprotein (RNP) particles are the heterogeneous
nuclear ribonucleoproteins (hnRNPs) that recognize AU-
rich elements (ARE) and coordinate expression of mRNAs at
the level of nuclear-cytoplasmic shuttling [65], cytoplasmic
mRNA turnover [66], and silencing of cell state- and type-
speciﬁc mRNAs [67, 68]. The ARE is located in the 3
untranslated region of many short-lived transcripts from
cytokines, proto-oncogenes, growth factors, or cell cycle reg-
ulators[69].Interestingly,tristetraprolin(TTP)andbutyrate
response factor (BRF1) belong to the same protein family
and both promote ARE-dependent decay [70]. Interferon γ
(IFNγ) suppresses the survival and expansion of T-helper
17 (Th17) cells by inducing expression of TTP, resulting in
the destabilisation of the p19 mRNA, coding for a subunit
of IL23 [71, 72]. The tight regulation of proinﬂammatory
cytokines through mRNA stability is required to suppressComparative and Functional Genomics 5
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Figure 2: Translation initiation control during growth factor stimulation, cellular stress, and cellular physiology. Growth factor addition
activates the PI3K/PKB/mTOR pathway releasing the limiting translation initiation factor 4E (eIF4E) from a repression complex with 4EBP
and activating S6K resulting in enhanced cap-dependent translation eﬃciency of structured mRNAs and ribogenesis. Interestingly, the
tumour suppressor proteins PTEN, Tsc1/2, and Pp2a are involved in attenuating this pathway. Another limiting initiation factor, eIF2α,i s
involved in providing methionine-tRNA in a complex with the 60S ribosome subunit to start peptide synthesis once the proper AUG is
recognised. eIF2 is phosphorylated by GCN2, PEK, HRI, or PRK in response to various stress conditions. Low levels of eIF4E and eIF2-GTP
as a result of 4EBP repression or stress-induced eIF2 phosphorylation, respectively, repress cap-dependent translation. These conditions are
optimal for translation initiation from Internal Ribosomal Entry Sites (IRESs). The levels of eIFs modulate translation initiation and this
depends on the codes oﬀered by the transcripts. Some transcripts are ideal to be translated under stress conditions having IRES structures in
their 5UTRs; others have secondary structures that are diﬃcult to melt and hence hinder the scanning process. The presence of uORFs,
attenuates translation initiation and also has a role in protein isoform formation. RNA-binding proteins modulate speciﬁc mRNAs by
stabilising, silencing, or activating the transcripts. These RNA/protein complexes (RNPs) have an important role in cellular physiology.
Some RNPs respond to oncogenic signals, while others are covalently modiﬁed and drive translation in response to terminal diﬀerentiation
signals as in the case of the DICE elements (translation initiation factors in bold).
inﬂammatory responses. In fact, TTP deﬁcient mice have an
overproduction of cytokines resulting in a systemic inﬂam-
matory response with clinical outcomes including arthritis
and autoimmunity [73].
IncontrasttoTTPandBrf1,membersoftheELAVfamily
ofRNA-bindingproteins(e.g.,HuR)bindandstabilizeARE-
containing transcripts [74]. Interestingly, in the context of
a closed loop model of translated eukaryotic mRNAs, the
recruitment of HuR and other RNA binding proteins to
3UTR elements results in the formation of complexes
between HuR and the scanning ribosome at the 5UTR. This
stabilises the transcript and facilitates translation initiation
at the proper AUG in transcripts with a structured 5UTR
[75]. Upregulation of TNFalpha in a mouse model for auto-
immune disease depends on binding of ELAV-like protein to
the AU-rich elements in its 3UTR [76].6 Comparative and Functional Genomics
Low cellular
iron levels
HRI
kinase
Enhanced
binding of
IRP to IRE
Ferritin mRNA
TfR mRNA
High
level
Low
expression
Heme
biosynthesis
Globins
expression
Global
protein
synthesis
Structured
mRNA
translation
Alternative
selection
of AUGs
Truncated
isoforms
SCL
Erythroid
lineage
commitment Erythroid
terminal diﬀerentiation
Granulocytic
terminal diﬀerentiation
Full length
C/EBPα
C/EBPα
p30
miR-223
NF1-A
Enhanced
expression
of
hnRNPE2
PI3K/mTOR SET α4
NF1-A
mRNA
Fusion protien
BCR/ABL
Constitutive
active RTKs
Growth factor
stimulation
pp2a
High
elFs
activity
High
eIF4E
activity
High
eIF2α
activity
Figure 3: Translation initiation control relays signals to erythroid and granulocytic diﬀerentiation. SCF binds c-kit, a Receptor Tyrosine
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in the UTRs of ferritin and transferrin modulates iron uptake and storage in accordance to demand of haeme. Low cellular iron levels
trigger phosphorylation of eIF2α to reduce the production of globin proteins. High eIFs levels also regulate commitment to the erythroid
or megakaryocytic lineage by selective usage of AUGs in the SCL transcript driving diﬀerent isoform production. The same mechanism is
used to produce truncated isoforms of the transcription factor C/EBPα that acts as a dominant negative form of the full length and hence
inhibits granulocytic terminal diﬀerentiation. Another form of translation control is involved in regulation of C/EBPα transcription activity.
Full-length C/EBPα enhances transcription of micro RNA 223 (miRNA-223), an inhibitor of NFI-A translation. NFI-A is a competitor for
binding C/EBPα DNA sites and hence its inhibition results in a positive feedback loop driving granulocytic diﬀerentiation. In addition to
transcriptioninhibitionoffull-lengthC/EBPαdrivenbyselectiveAUGusageortranslationsilencingofcompetitors,theroleofRNA-binding
proteins is important in modulating terminal diﬀerentiation. BCR/ABL enhances the expression of hnRNPE2 that binds the UTR of C/EBPα
transcript and inhibits translation.
Modiﬁcation of RNA binding-proteins by signalling can
be another level of regulating translation eﬃciency at the
proper AUG. Silencing of transcripts by binding of hnRNP K
and hnRNP E1 to diﬀerentiation control element (DICE) in
the 3 UTR of 15-lipoxygenase (LOX) mRNA transcript [67]
can be released during terminal erythroid diﬀerentiation by
phosphorylation of hnRNP K (Figure 2)[ 77].
Another prototype example in which RNA-binding pro-
teins regulate translation in hematopoietic cells is the iron-
response element (IRE) [78]. It is a stem-loop structure that
binds iron regulatory proteins IRP1 and IRP2 dependent on
their association with iron [79, 80]. Whereas the free IRE can
easily be unwound by the eIF4A helicase during scanning of
the preinitiation complex, IRP binding stabilises the stem-
loop structure and impairs continued scanning and transla-
tion. Initially characterised for ferritin mRNA, IRE elements
are found in a number of transcripts encoding proteins
involved in iron metabolism or hemoglobin synthesis. An
example of the latter is alpha-hemoglobin-stabilizing protein
(AHSP) mRNA. Because alpha globin is synthesised ahead of
beta globin, it has to be stabilised until its incorporation into
haemoglobin.RegulationofAHSPbyironimpliesregulation
of the stability of alpha globin [81].
Ceruloplasmin is involved in iron metabolism and is
translationally regulated by interferon gamma [82]. Phos-
phorylation of ribosomal protein L13a by interferon-gamma
resultsindissociationofL13afromthe60Sribosomesubunit
and recruitment of an Rpl13-containing protein complex
to a structural element in the 3UTR of ceruloplasmin
[83] resulting in translation repression. This mechanism
incorporates 2 novel issues. First, the ribosome is able to
present signalling sensitive factors that can be released toComparative and Functional Genomics 7
attenuate translation of speciﬁc transcripts without aﬀecting
global synthesis rates. Second, regulatory elements in the
3UTR recruit protein complexes within the circular mature
transcripts and interact with scanning complexes in the
5UTR, hence modulating translation initiation eﬃciency.
The expression of RNA-binding proteins that attenuate
translation of speciﬁc subsets of mRNAs has been implicated
in the transition from chronic CML to blast crisis events
[84, 85]. For instance, ectopic expression of hnRNP E2, an
RNA-bindingproteinupregulatedduringblastcrisisofCML,
resulted in downregulation of C/EBPα (Figure 3)a n dG -
CSFR in myeloid progenitor cells, inhibiting granulocytic
diﬀerentiation [86].
3. Conclusion andFuturePerspectives
Regulation of gene expression has been studied extensively
in disease models and patient groups giving detailed annota-
tionsofthediﬀerentialexpressionattheleveloftranscription
regulation. Diﬀerential expression between the transcrip-
tome and the proteome supports the importance of post-
transcriptional regulation. Increasing evidence supports the
prominent and so far underestimated regulation of mRNA
translation, which depends on the availability and activity
of the translation machinery, the structure of the transcript,
and the expression of RNA binding proteins. Growth factor
signaling enhances polysome recruitment of speciﬁc RNA
transcripts, with marginal eﬀect on the transcription regula-
tion [23]. Similarly, increased availability of the translation
initiation factor, eIF4E, through growth factor signaling,
overexpression studies, and suppressions of the attenuation
mechanismofmTORsignalingresultsinproliferativeadvan-
tageoferythroidprogenitorsandblockofdiﬀerentiation[12,
14]. Increasingly, diﬀerential or conditional expression of
transcripts are being associated with haematological malig-
nancies, including expression of dominant negative isoforms
involved in progenitor diﬀerentiation [52], expression of
RNA binding proteins involved in inﬂammatory responses
[71], and suppressed expression of phosphatase subunits
resultinginprogressionofdisease[40].Interestingly,deregu-
lationofnegativefeedbackmechanismsduetolowactivityof
phosphatases is potentially targeted using mTOR inhibitors
or phosphatase activators. Hence understanding transla-
tional control mechanisms and its deregulation in disease
will impact on patient stratiﬁcation into therapeutic groups.
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